Table 4.
: Characteristics of cohort of COVID-19 patients in studies on ILCs cells.
| Adult/Child | Severe | Non-Severe | Non-COVID-19 in ICU | Recovered | Healthy Subject | |
|---|---|---|---|---|---|---|
| Garcia 2021 Clinical and translational Immunology [55] | Adult. N = 23 pts; N = 16 HCs. | N = 12 pts in ICU with IMV | N = 11 pts; Non-intubated and Non-oxygen need. Some hospedalized ICU. | ND | ND | N = 16 |
| ↑males↓females | MA: 59.5 y | MA: 56 y | ||||
| Median days hospitalized: 11 d for moderate pts; 22 d for severe pts. | 83% males | 63.6% males. | ||||
| Segundo 2020 Biomedicines [58] | Adult. N = 150 pts divided based on oxygen therapy requirements. | N = 82 mod/sev (ICU with IMV or only hospitalized or deceased) | N = 73 Mild pts | ND | ND | ND |
| MA: 72 y | MA: 59 y | |||||
| ↑ male gender. | ↑ female gender. | |||||
| Silverstein 2021 (preprint) [56] | Adult cohort of samples | N = 40 pts. Among whom N=33 (82.5%) at ICU; N=32 (80%) with IMV; N=7 (17.5%) died. | N = 51 outpatients infected with SARS-CoV-2 who were treated for COVID-19. | ND | ND | N = 86 who donated blood prior to the SARS-CoV-2 outbreak. |
| ↓males ↑ females | MA: 57.6 y | MA: 36.8 y | MA: 50.9 y | |||
| Mean days hospitalized: 34.2 d | 60% males gender | 25.5% males gender | 55.8% males | |||
| Pediatric. N = 30 pts; N = 17 HCs. | N = 11 pts. Among whom N = 1 (5.3%) at ICU with IMV | N = 8 outpatients infected with SARS-CoV-2 | N = 11 MIS-C pts | N = 14 COVID-19 follow-up; N = 7 MIS-C follow-up; N = 10 pts (5 COVID-19 and 5 MIS-C) | N = 17 SARS-CoV-2-uninfected pediatric blood donors | |
| ↑males ↓ females | MA: 13 y | MA: 13 y | ||||
| Gomez-Cadena 2021 Cellular & Molecular Immunology [57] | Adult. N = 60 pts hospitalized for COVID-19. males = females |
N = 30 pts MA: 68.3 with 41% of the severe pts were older than 75 y |
N = 30 with mild symptoms. MA: 39.8 y |
ND | ND | N = 21 |
| Pts were enrolled at least 21 d after the first symptoms of COVID-19 | 76.7% males | 23.3% males | ||||
| Gomez 2021 Eur. J. Immunology [58] | Adult. N = 20 pts hospitalized for COVID-19. Days of symptoms to admission: 12 d. |
N = 20 pts 11/20 pts in ICU 80% males MA: 56 y |
ND | ND |
N = 14 pts in follow-up. Days of symptoms to recovery: 19 d |
N = 9MA: 58 y |
AD: Acute disease; COVID-19: Coronavirus Disease-19; DIC: Disseminated intravascular coagulation; HC: healthy control; ICU: Intensive care Unit; MDS: Median duration of symptoms before admission in ICU; IMV: Invasive mechanical ventilation; LPS: Lipopolysaccharides; MA: Mean age; MDH: Median days of hospitalization; MIS-C: Multisystem Inflammatory Syndrome in Children. MND: Median number of days from clinical onset to sampling; N: Number; NHC: Nonpregnant healthy controls; NP: Nonpregnant patients; NPCov: Nonpregnant COVID-19 patients; NPCovM: Nonpregnant COVID-19 patients with Moderate symptoms. NPCovS: Nonpregnant COVID-19 patients with Severe symptoms. PCovM: Pregnant COVID-19 patients with Moderate symptoms; PCovS: Pregnant COVID-19 patients with Severe symptoms; pts: Patients; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; y: Years.